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Potential control of antipsychotic-induced hyperprolactinemia and obesity in
children and adolescents by aripiprazole
Abstract
The paper published in your journal by Migiliardi et al. (2009) reported that increased hyperprolactinemia
is a major side-effect of risperidone and olanzapine treatment in children and adolescents. They showed
that risperidone could cause 10 times higher prolactin levels than olanzapine treatment in children and
adolescents. This was a well-designed study that controlled for dose, gender, and individual differences,
as well as response differences to treatment duration (Migliardi et al. 2009). However, another important
issue that should be considered, but was not reported in this study, is antipsychotic-induced weight gain/
obesity. Clinical data have demonstrated that weight gain is a major side-effect induced by atypical
antipsychotics, which may lead to medical and social consequences, such as type II diabetes,
cardiovascular disease. It is particularly important that children and adolescents are more sensitive than
adults to atypical antipsychotic-induced weight gain/obesity, and other metabolic side-effects (Correll
2008). Clinical studies have shown that olanzapine treatment can cause far greater weight gain than
risperidone in both adult and child/adolescent patients (Correll 2008). Therefore, it would be of great
value to present body weight data along with prolactin data in Migliardi et al.’s study.
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Sir,
The paper published in your journal by Migiliardi et al. (2009) reported that increased
hyperprolactinemia is a major side-effect of risperidone and olanzapine treatment in children
and adolescents. They showed that risperidone could cause 10 times higher prolactin levels
than olanzapine treatment in children and adolescents. This was a well-designed study that
controlled for dose, gender, and individual differences, as well as response differences to
treatment duration (Migliardi et al. 2009). However, another important issue that should be
considered, but was not reported in this study, is antipsychotic-induced weight gain/obesity.
Clinical data have demonstrated that weight gain is a major side-effect induced by atypical
antipsychotics, which may lead to medical and social consequences, such as type II diabetes,
cardiovascular disease. It is particularly important that children and adolescents are more
sensitive than adults to atypical antipsychotic-induced weight gain/obesity, and other
metabolic side-effects (Correll 2008). Clinical studies have shown that olanzapine treatment
can cause far greater weight gain than risperidone in both adult and child/adolescent patients
(Correll 2008). Therefore, it would be of great value to present body weight data along with
prolactin data in Migliardi et al.’s study.

One key issue is how to control antipsychotic-induced hyperprolactinemia and weight gain at
the same time. Prolactin is secreted from pituitary lactotroph cells and primarily inhibited by
dopamine D2 receptors. As D2 receptor antagonists, blockage of D2 receptors in the
dopaminergic tubero-infundibular pathway has been suggested as a major mechanism for
antipsychotic-induced hyperprolactinemia (Correll 2008). In fact, the relative incidence of
hyperprolactinemia (roughly Risperidone > Haloperidol > Olanzapine > Ziprasidone >
Quetiapine > Clozapine > Aripiprazole) could be predicted by their potency as D2 antagonists
(Correll and Carlson 2006). Aripiprazole has even been reported to decrease prolactin
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secretion in adults (Hoffer et al. 2009). On the other hand, H1 receptor antagonist properties
are the main predictor for the development of antipsychotic-induced weight gain
(approximately Clozapine > Olanzapine > Risperidone > Haloperidol > Ziprasidone >
Aripiprazole (Correll 2008). Consistent with these findings, olanzapine significantly reduced
H1 receptor mRNA expression in the hypothalamic arcuate nucleus (Arc) and ventromedial
hypothalamic nucleus, and H1 receptor mRNA expression in the Arc was negatively
correlated with food intake and fat mass (Han et al. 2008). It is very interesting that
olanzapine- and clozapine-induced weight gain/obesity can be successfully controlled by coadministration with aripiprazole in adult schizophrenia patients, without reducing the original
olanzapine and clozapine doses (Henderson et al. 2009). Aripiprazole was developed as a
potent D2 partial-agonist, 5-HT1A partial-agonist, and also 5-HT2A antagonist (DeLeon et al.
2004). However, aripiprazole has a low histaminergic antagonism and does not affect H1
receptor expression (DeLeon et al. 2004; Han et al. 2008). Instead, aripiprazole is not a simple
partial-agonist, but a functionally selective drug that can act as a D2 agonist or D2 antagonist
depending on different brain regions (Han et al. 2009). Based on these findings, we recently
suggested that aripiprazole’s D2 agonistic property may account for the effect of aripiprazole
in reducing olanzapine-induced obesity (Deng et al. 2010). It is possible that a coadministration

of

aripiprazole

could

be

used

to

control

risperidone-induced

hyperprolactinaemia through its D2 agonistic effect. In fact, a recent study has found that
risperidone treatment adjunctive with aripiprazole significantly decreased ~10 times prolactin
levels compared to adjunctive placebo in adults (Kane et al. 2009). It is very important that
aripiprazole has been approved by the FDA to be used in youths (aged 13 years and older) for
schizophrenia and bipolar disorder, as well as for autism spectrum disorder in children aged 6
to 17 years in 2009. Therefore, it is possible to use aripiprazole in children or adolescents to
reduce both olanzapine-induced weight gain and risperidone-induced hyperprolactinemia.
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However, further animal studies and clinical trials are necessary before any extended practices
are adopted in the paediatric clinics.
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